Louis-Armstrong

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical…

Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study

Resveratrol has been used in humans, and previous data show that its toxicity is limited13. Since…